Pure Global

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease. - Trial 2014-004531-39

Access comprehensive clinical trial information for 2014-004531-39 through Pure Global AI's free database. This phase not specified trial is sponsored by Abbott Deutschland GmbH & Co. KG and is currently status unknown. The study focuses on Crohn's Disease.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2014-004531-39
Trial Details
EU Clinical Trials Register โ€ข 2014-004531-39
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease.

Study Focus

Crohn's Disease

Sponsor & Location

Abbott Deutschland GmbH & Co. KG

Abbott Japan

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

ICD-10 Classifications

Crohn disease, unspecified
Other Crohn disease
Crohn disease of large intestine
Crohn disease [regional enteritis]
Crohn disease of small intestine

Data Source

EU Clinical Trials Register

2014-004531-39

Non-Device Trial